vascular pattern, and mucosal erythema. Endoscopic remission, if understood literally, cannot be anything but the restitution of colonic mucosa to its original aspect. A few war wounds can be accepted, such as fibrous scars, mucosal bridges, or even pseudopolyps, but mucosal elasticity, shine, resilience, and vascular pattern have to come back to normal. However, in the anti-TNF pivotal trials the bar went down, 6, 7, 8, 9 and both Mayo 0 and Mayo 1 were considered to represent mucosal healing. Maybe it was important to ensure that the efficacy of biologicals was adequately represented, but the message sunk in and conventions initially defined and accepted for the initial stages of clinical research, reached real life and went ahead unquestioned.
Nevertheless, something stood out in all these pivotal studies: although it would make sense to consider endoscopic remission as a more difficult target than clinical remission, this was not the case in either the ACT, the ULTRA, or the PURSUIT studies [ Figure 1 ]. Also, clinicians very soon started appreciating differences between Mayo 0 endoscopic remission and Mayo 1 endoscopic remission: the latter was a predictor of a higher probability of clinical recurrence.
In this issue of the Journal of Crohn's and Colitis, Barreiro and coworkers 11 contribute with an elegant prospective longitudinal cohort study in which patients with UC in remission were followed up for 1 year. The authors clearly showed that the probability of relapse diverged significantly between Mayo 0 and Mayo 1 patients, both at 6 and at 12 months of follow-up. This was true for any extension of disease, and was supported by a more frequent need of treatment escalation in the Mayo 1 subgroup. Their methodology is precise, and conforms to the requirements defined both by the original Mayo index description and by ECCO consensus on the definition of relapse. 12 The lack of histological correlation and of calprotectin determinations is a limitation of this study, but is not likely to substantially affect conclusions, and instead opens ways for further research.
In a smaller, retrospective study, also included in this issue of ECCO-JCC, Boal Carvalho et al. 14 Recent consensuses on activity measurement in IBD are still considering traditional indexes, but the importance assigned to other measurements, such as patient-reported outcomes and objective measures of activity [including endoscopy], is continuously growing. 15 Although inter-observer correlation is far from optimal, endoscopy is a semiquantifiable exploration, reproducible and accessible to centralised reading. New indexes, such as the Ulcerative Colitis Endoscopic Index of Severity [UCEIS], have to be explored. Medical societies could help ensure their uniform application; in this sense, ECCO will soon include in its website a workshop on UCEIS, which could be an important step towards this objective.
In conclusion, this controversy teaches us a lesson: we should not immediately transfer definitions adopted in pivotal trials, which might be more exploratory than clinically significant, to daily clinical practice. Our patients are not similar to those included in pivotal trials, 16 and neither are our follow-up schedules, our concomitant medications, or our definitions [and the patients' perceptions] of response, remission, and treatment success. Studies such as those published in this issue of ECCO-JCC show us that clinical judgement is best applied before accepting the hot results of clinical research as the ultimate guides or translating their concepts and jargon into daily practice.
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